Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.62 |
| ▸ | TSPO | P30536 | 3/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 10/20 | 0.52 |
| ▸ | OXTR | P30559 | 4/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20276907 | 1.00 | IDH1 (0.62) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL26565761 | 1.00 | IDH1 (0.62) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277553 | 0.99 | IDH1 (0.60) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL30046512 | 0.99 | IDH1 (0.60) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL30045597 | 0.94 | IDH1 (0.57) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277508 | 0.94 | IDH1 (0.57) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277224 | 0.90 | IDH1 (0.64) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL30045647 | 0.90 | IDH1 (0.64) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL26565887 | 0.90 | AVPR1A (0.54) | IDH1TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL4318816 | 0.89 | IDH1 (0.53) | IDH1TSPOAVPR1AOXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | OXTR, AVPR1B, AVPR1A | IDH1 4620/4885TSPO 478/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.